Related Experiment Video
Updated: May 18, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Liver-specific contrast agents
1Department of Diagnostic Radiology, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. dow-mu.koh@icr.ac.uk
Abstract:
In the patient with cancer, magnetic resonance imaging is increasingly used as a diagnostic tool for disease detection, lesion characterization, as well as the assessment of treatment response. Although non-contrast T1-weighted and T2-weighted imaging, together with low molecular weight extracellular gadolinium contrast-enhanced T1-weighted magnetic resonance imaging remain the cornerstone for liver assessment, there is increasing recognition of the benefits of liver-specific contrast agents for disease evaluation.
